{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:44:55Z","timestamp":1762004695784},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,1,28]],"date-time":"2015-01-28T00:00:00Z","timestamp":1422403200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s11102-015-0639-4","type":"journal-article","created":{"date-parts":[[2015,1,27]],"date-time":"2015-01-27T02:01:10Z","timestamp":1422324070000},"page":"238-244","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pituitary-directed medical therapy in Cushing\u2019s disease"],"prefix":"10.1007","volume":"18","author":[{"given":"Stephan","family":"Petersenn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,28]]},"reference":[{"issue":"7","key":"639_CR1","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","volume":"93","author":"BM Biller","year":"2008","unstructured":"Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement. J Clin Endocrinol Metab 93(7):2454\u20132462. doi: 10.1210\/jc.2007-2734","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"639_CR2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11102-012-0397-5","volume":"15","author":"M Fleseriu","year":"2012","unstructured":"Fleseriu M, Petersenn S (2012) Medical management of Cushing\u2019s disease: what is the future? Pituitary 15(3):330\u2013341. doi: 10.1007\/s11102-012-0397-5","journal-title":"Pituitary"},{"issue":"Suppl 1","key":"639_CR3","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S1521-690X(09)70004-1","volume":"23","author":"PM Stewart","year":"2009","unstructured":"Stewart PM, Petersenn S (2009) Rationale for treatment and therapeutic options in Cushing\u2019s disease. Best Pract Res Clin Endocrinol Metab 23(Suppl 1):S15\u2013S22. doi: 10.1016\/S1521-690X(09)70004-1","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"639_CR4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/MED.0b013e3283631809","volume":"20","author":"LK Nieman","year":"2013","unstructured":"Nieman LK (2013) Update in the medical therapy of Cushing\u2019s disease. Curr Opin Endocrinol Diabetes Obes 20(4):330\u2013334. doi: 10.1097\/MED.0b013e3283631809","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"639_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-013-1151-1","volume":"114","author":"M Fleseriu","year":"2013","unstructured":"Fleseriu M, Petersenn S (2013) New avenues in the medical treatment of Cushing\u2019s disease: corticotroph tumor targeted therapy. J Neurooncol 114(1):1\u201311. doi: 10.1007\/s11060-013-1151-1","journal-title":"J Neurooncol"},{"issue":"2","key":"639_CR6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11154-008-9082-4","volume":"10","author":"C Bruin de","year":"2009","unstructured":"de Bruin C, Feelders RA, Lamberts SW, Hofland LJ (2009) Somatostatin and dopamine receptors as targets for medical treatment of Cushing\u2019s syndrome. Rev Endocr Metab Disord 10(2):91\u2013102. doi: 10.1007\/s11154-008-9082-4","journal-title":"Rev Endocr Metab Disord"},{"issue":"10","key":"639_CR7","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1210\/jc.2012-2328","volume":"97","author":"F Pecori-Giraldi","year":"2012","unstructured":"Pecori-Giraldi F, Ambrogio AG, Andrioli M, Sanguin F, Karamouzis I, Corsello SM, Scaroni C, Arvat E, Pontecorvi A, Cavagnini F (2012) Potential role for retinoic acid in patients with Cushing\u2019s disease. J Clin Endocrinol Metab 97(10):3577\u20133583. doi: 10.1210\/jc.2012-2328","journal-title":"J Clin Endocrinol Metab"},{"key":"639_CR8","doi-asserted-by":"crossref","unstructured":"Stefaneanu L, Kovacs K, Horvath E, Buchfelder M, Fahlbusch R, Lancranjan L (2001) Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine 14(3):329\u2013336","DOI":"10.1385\/ENDO:14:3:329"},{"issue":"5","key":"639_CR9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2265.1981.tb00691.x","volume":"15","author":"EF Adams","year":"1981","unstructured":"Adams EF, Ashby MJ, Brown SM, White MC, Mashiter K (1981) Bromocriptine suppresses ACTH secretion from human pituitary tumour cells in culture by a dopaminergic mechanism. Clin Endocrinol (Oxf) 15(5):479\u2013484","journal-title":"Clin Endocrinol (Oxf)"},{"key":"639_CR10","doi-asserted-by":"crossref","unstructured":"Yin D, Kondo S, Takeuchi J, Morimura T (1994) Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine. FEBS Lett 339(1\u20132):73\u201375","DOI":"10.1016\/0014-5793(94)80387-0"},{"issue":"4","key":"639_CR11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1210\/edrv-14-4-443","volume":"14","author":"JW Miller","year":"1993","unstructured":"Miller JW, Crapo L (1993) The medical treatment of Cushing\u2019s syndrome. Endocr Rev 14(4):443\u2013458","journal-title":"Endocr Rev"},{"issue":"2","key":"639_CR12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2265.1988.tb03658.x","volume":"28","author":"AC Hale","year":"1988","unstructured":"Hale AC, Coates PJ, Doniach I, Howlett TA, Grossman A, Rees LH, Besser GM (1988) A bromocriptine-responsive corticotroph adenoma secreting alpha-MSH in a patient with Cushing\u2019s disease. Clin Endocrinol (Oxf) 28(2):215\u2013223","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"639_CR13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2265.1986.tb03621.x","volume":"25","author":"HP Koppeschaar","year":"1986","unstructured":"Koppeschaar HP, Croughs RJ, Thijssen JH, Schwarz F (1986) Response to neurotransmitter modulating drugs in patients with Cushing\u2019s disease. Clin Endocrinol (Oxf) 25(6):661\u2013667","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"639_CR14","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1210\/jc.2003-030837","volume":"89","author":"R Pivonello","year":"2004","unstructured":"Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SW (2004) Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89(5):2452\u20132462","journal-title":"J Clin Endocrinol Metab"},{"key":"639_CR15","doi-asserted-by":"crossref","unstructured":"Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, Hofland LJ, Lamberts SW, Colao A (2009) The medical treatment of Cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94(1):223\u2013230. doi: 10.1210\/jc.2008-1533","DOI":"10.1210\/jc.2008-1533"},{"issue":"5","key":"639_CR16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1530\/EJE-10-0382","volume":"163","author":"A Godbout","year":"2010","unstructured":"Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A (2010) Cabergoline monotherapy in the long-term treatment of Cushing\u2019s disease. Eur J Endocrinol 163(5):709\u2013716. doi: 10.1530\/EJE-10-0382","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"639_CR17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11102-011-0309-0","volume":"15","author":"MP Manavela","year":"2012","unstructured":"Manavela MP, Danilowicz K, Bruno OD (2012) Macrocorticotropinoma shrinkage and control of hypercortisolism under long-term cabergoline therapy: case report. Pituitary 15(Suppl 1):33\u201336. doi: 10.1007\/s11102-011-0309-0","journal-title":"Pituitary"},{"key":"639_CR18","author":"A Ahmed","year":"2012","unstructured":"Ahmed A, Furqan S, Islam N (2012) Disappearance of pituitary macro adenoma with combination of ketoconazole and cabergoline treatment: an unusual case of Cushing\u2019s syndrome with interesting findings. BMJ Case Rep. doi: 10.1136\/bcr.03.2012.6025","journal-title":"BMJ Case Rep"},{"issue":"6","key":"639_CR19","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1210\/er.2004-0025","volume":"26","author":"JR Lindsay","year":"2005","unstructured":"Lindsay JR, Nieman LK (2005) The hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment. Endocr Rev 26(6):775\u2013799. doi: 10.1210\/er.2004-0025","journal-title":"Endocr Rev"},{"issue":"5","key":"639_CR20","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1210\/jc.2004-2361","volume":"90","author":"JR Lindsay","year":"2005","unstructured":"Lindsay JR, Jonklaas J, Oldfield EH, Nieman LK (2005) Cushing\u2019s syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab 90(5):3077\u20133083. doi: 10.1210\/jc.2004-2361","journal-title":"J Clin Endocrinol Metab"},{"issue":"2 Pt 2","key":"639_CR21","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/AOG.0b013e31829e398a","volume":"122","author":"I Woo","year":"2013","unstructured":"Woo I, Ehsanipoor RM (2013) Cabergoline therapy for Cushing disease throughout pregnancy. Obstet Gynecol 122(2 Pt 2):485\u2013487. doi: 10.1097\/AOG.0b013e31829e398a","journal-title":"Obstet Gynecol"},{"issue":"1","key":"639_CR22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"R Schade","year":"2007","unstructured":"Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356(1):29\u201338. doi: 10.1056\/NEJMoa062222","journal-title":"N Engl J Med"},{"issue":"1","key":"639_CR23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"R Zanettini","year":"2007","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N Engl J Med 356(1):39\u201346. doi: 10.1056\/NEJMoa054830","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"639_CR24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000314293","volume":"92","author":"M Boschetti","year":"2010","unstructured":"Boschetti M, Gatto F, Arvigo M, Esposito D, Rebora A, Talco M, Albertelli M, Nazzari E, Goglia U, Minuto F, Ferone D (2010) Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells. Neuroendocrinology 92(Suppl 1):17\u201322. doi: 10.1159\/000314293","journal-title":"Neuroendocrinology"},{"key":"639_CR25","doi-asserted-by":"crossref","unstructured":"Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146(5):707\u2013716\u00a0doi: 10.1530\/eje.0.1460707","DOI":"10.1530\/eje.0.1460707"},{"issue":"Suppl 1","key":"639_CR26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000080741","volume":"80","author":"HA Schmid","year":"2004","unstructured":"Schmid HA, Schoeffter P (2004) Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80(Suppl 1):47\u201350. doi: 10.1159\/000080741","journal-title":"Neuroendocrinology"},{"issue":"4","key":"639_CR27","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.01876","volume":"152","author":"LJ Hofland","year":"2005","unstructured":"Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW (2005) The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152(4):645\u2013654. doi: 10.1530\/eje.1.01876","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"639_CR28","doi-asserted-by":"crossref","first-page":"E278","DOI":"10.1152\/ajpendo.00004.2005","volume":"289","author":"J Hoek van der","year":"2005","unstructured":"van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW, Hofland LJ (2005) Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 289(2):E278\u2013E287. doi: 10.1152\/ajpendo.00004.2005","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"11","key":"639_CR29","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2006-1245","volume":"91","author":"DL Batista","year":"2006","unstructured":"Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A (2006) The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91(11):4482\u20134488. doi: 10.1210\/jc.2006-1245","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"639_CR30","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1530\/eje.1.01914","volume":"152","author":"AP Silva","year":"2005","unstructured":"Silva AP, Bethmann K, Raulf F, Schmid HA (2005) Regulation of ghrelin secretion by somatostatin analogs in rats. Eur J Endocrinol 152(6):887\u2013894. doi: 10.1530\/eje.1.01914","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"639_CR31","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1210\/jc.2009-1311","volume":"94","author":"A Ben-Shlomo","year":"2009","unstructured":"Ben-Shlomo A, Schmid H, Wawrowsky K, Pichurin O, Hubina E, Chesnokova V, Liu NA, Culler M, Melmed S (2009) Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab 94(11):4342\u20134350. doi: 10.1210\/jc.2009-1311","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"639_CR32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","volume":"94","author":"M Boscaro","year":"2009","unstructured":"Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J (2009) Treatment of pituitary-dependent Cushing\u2019s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94(1):115\u2013122. doi: 10.1210\/jc.2008-1008","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"639_CR33","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11102-013-0503-3","volume":"17","author":"M Boscaro","year":"2014","unstructured":"Boscaro M, Bertherat J, Findling J, Fleseriu M, Atkinson AB, Petersenn S, Schopohl J, Snyder P, Hughes G, Trovato A, Hu K, Maldonado M, Biller BM (2014) Extended treatment of Cushing\u2019s disease with pasireotide: results from a 2-year, Phase II study. Pituitary 17(4):320\u2013326. doi: 10.1007\/s11102-013-0503-3","journal-title":"Pituitary"},{"issue":"10","key":"639_CR34","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BMK (2012) A 12-month phase 3 study of pasireotide in Cushing\u2019s Disease. N Engl J Med 366(10):914\u2013924. doi: 10.1056\/NEJMoa1105743","journal-title":"N Engl J Med"},{"issue":"1","key":"639_CR35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-13-1013","volume":"171","author":"SM Webb","year":"2014","unstructured":"Webb SM, Ware JE, Forsythe A, Yang M, Badia X, Nelson LM, Signorovitch JE, McLeod L, Maldonado M, Zgliczynski W, de Block C, Portocarrero-Ortiz L, Gadelha M (2014) Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing\u2019s disease. Eur J Endocrinol 171(1):89\u201398. doi: 10.1530\/EJE-13-1013","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"639_CR36","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cen.12431","volume":"81","author":"R Pivonello","year":"2014","unstructured":"Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Trovato A, Hughes G, Salgado LR, Lacroix A, Schopohl J, Biller BM, Pasireotide BSG (2014) Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing\u2019s disease: results from a Phase III study. Clin Endocrinol (Oxf) 81(3):408\u2013417. doi: 10.1111\/cen.12431","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"639_CR37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1530\/EJE-13-0477","volume":"170","author":"R Pas van der","year":"2014","unstructured":"van der Pas R, van Esch JH, de Bruin C, Danser AH, Pereira AM, Zelissen PM, Netea-Maier R, Sprij-Mooij DM, van den Berg-Garrelds IM, van Schaik RH, Lamberts SW, van den Meiracker AH, Hofland LJ, Feelders RA (2014) Cushing\u2019s disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy. Eur J Endocrinol 170(2):181\u2013191. doi: 10.1530\/EJE-13-0477","journal-title":"Eur J Endocrinol"},{"key":"639_CR38","doi-asserted-by":"crossref","unstructured":"MacKenzie-Feder J, Bourdeau I, Vallette S, Beauregard H, Ste-Marie LG, Lacroix A (2014) pasireotide monotherapy in Cushing\u2019s disease: a single-centre experience with 5-year extension of phase III Trial. Pituitary 17(6):519\u2013529. doi: 10.1007\/s11102-013-0539-4","DOI":"10.1007\/s11102-013-0539-4"},{"issue":"2","key":"639_CR39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2265.2008.03486.x","volume":"71","author":"K Cukier","year":"2009","unstructured":"Cukier K, Tewari R, Kurth F, Schmid HA, Lai C, Torpy DJ (2009) Significant response to pasireotide (SOM230) in the treatment of a patient with persistent, refractory Cushing\u2019s disease. Clin Endocrinol (Oxf) 71(2):305\u2013307. doi: 10.1111\/j.1365-2265.2008.03486.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"639_CR40","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11102-012-0427-3","volume":"15","author":"I Shimon","year":"2012","unstructured":"Shimon I, Rot L, Inbar E (2012) Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review. Pituitary 15(4):608\u2013613. doi: 10.1007\/s11102-012-0427-3","journal-title":"Pituitary"},{"issue":"4","key":"639_CR41","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.4158\/EP12296.CR","volume":"19","author":"L Lu","year":"2013","unstructured":"Lu L, Duan L, Jin Z, Lu Z, Gu F (2013) Effective long-term treatment of Cushing\u2019s disease with pasireotide: a case report. Endocr Pract 19(4):e92\u2013e96. doi: 10.4158\/EP12296.CR","journal-title":"Endocr Pract"},{"key":"639_CR42","author":"L Trementino","year":"2014","unstructured":"Trementino L, Cardinaletti M, Concettoni C, Marcelli G, Boscaro M, Arnaldi G (2014) Up-to 5-year efficacy of pasireotide in a patient with Cushing\u2019s disease and pre-existing diabetes: literature review and clinical practice considerations. Pituitary. doi: 10.1007\/s11102-014-0582-9","journal-title":"Pituitary"},{"issue":"22","key":"639_CR43","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMc1204078","volume":"366","author":"R Libe","year":"2012","unstructured":"Libe R, Groussin L, Bertherat J (2012) Pasireotide in Cushing\u2019s disease. N Engl J Med 366(22):2134\u20132135. doi: 10.1056\/NEJMc1204078#SA2","journal-title":"N Engl J Med"},{"issue":"5","key":"639_CR44","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1210\/jc.2013-1497","volume":"98","author":"L Katznelson","year":"2013","unstructured":"Katznelson L (2013) Sustained improvements in plasma ACTH and clinical status in a patient with Nelson\u2019s syndrome treated with pasireotide LAR, a multireceptor somatostatin analog. J Clin Endocrinol Metab 98(5):1803\u20131807. doi: 10.1210\/jc.2013-1497","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"639_CR45","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/cen.12259","volume":"80","author":"S Petersenn","year":"2014","unstructured":"Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Sen K, Salgado LR, Colao A, Biller BM, Pasireotide BSG (2014) High variability in baseline urinary free cortisol values in patients with Cushing\u2019s disease. Clin Endocrinol (Oxf) 80(2):261\u2013269. doi: 10.1111\/cen.12259","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"639_CR46","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/ncpendmet0837","volume":"4","author":"T Carroll","year":"2008","unstructured":"Carroll T, Raff H, Findling JW (2008) Late-night salivary cortisol measurement in the diagnosis of Cushing\u2019s syndrome. Nat Clin Pract Endocrinol Metab 4(6):344\u2013350. doi: 10.1038\/ncpendmet0837","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"4","key":"639_CR47","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1530\/EJE-11-0945","volume":"166","author":"T Deutschbein","year":"2012","unstructured":"Deutschbein T, Broecker-Preuss M, Flitsch J, Jaeger A, Althoff R, Walz MK, Mann K, Petersenn S (2012) Salivary cortisol as a diagnostic tool for Cushing\u2019s syndrome and adrenal insufficiency: improved screening by an automatic immunoassay. Eur J Endocrinol 166(4):613\u2013618. doi: 10.1530\/EJE-11-0945","journal-title":"Eur J Endocrinol"},{"key":"639_CR48","author":"L Trementino","year":"2014","unstructured":"Trementino L, Cardinaletti M, Concettoni C, Marcelli G, Polenta B, Spinello M, Boscaro M, Arnaldi G (2014) Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing\u2019s disease. Pituitary. doi: 10.1007\/s11102-014-0557-x","journal-title":"Pituitary"},{"issue":"8","key":"639_CR49","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1172\/JCI11098","volume":"108","author":"M Paez-Pereda","year":"2001","unstructured":"Paez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E, Losa M, Stalla J, Grubler Y, Missale C, Arzt E, Stalla GK (2001) Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 108(8):1123\u20131131. doi: 10.1172\/JCI11098","journal-title":"J Clin Invest"},{"issue":"9","key":"639_CR50","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/en.2006-0414","volume":"147","author":"V Castillo","year":"2006","unstructured":"Castillo V, Giacomini D, Paez-Pereda M, Stalla J, Labeur M, Theodoropoulou M, Holsboer F, Grossman AB, Stalla GK, Arzt E (2006) Retinoic acid as a novel medical therapy for Cushing\u2019s disease in dogs. Endocrinology 147(9):4438\u20134444. doi: 10.1210\/en.2006-0414","journal-title":"Endocrinology"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-015-0639-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-015-0639-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-015-0639-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T00:43:18Z","timestamp":1566261798000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-015-0639-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,28]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["639"],"URL":"https:\/\/doi.org\/10.1007\/s11102-015-0639-4","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,28]]}}}